Shares of GRI Bio Inc. (GRI) are up over 180% at $1.68 in premarket trading Monday as the company gears up for a clinical trial event related to its lead drug candidate this quarter.
The lead asset, GRI-0621, being developed for the treatment of idiopathic pulmonary fibrosis (IPF), is a small molecule RAR-ß? dual agonist that inhibits the activity of human iNKT cells. In multiple animal models, iNKT inhibition has demonstrated fibrosis resolution, according to the company.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.